Results 21 to 30 of about 195,947 (275)

Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity

Microorganisms, 2021
Leishmaniasis, a chronic and persistent intracellular protozoal infection caused by many different species within the genus Leishmania, is an unfamiliar disease to most North American providers.
John M. Curtin, Naomi E. Aronson
doaj   +1 more source

Kidney involvement in leishmaniasis—a review

Brazilian Journal of Infectious Diseases, 2014
Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania transmitted by insects of the genus Lutzomyia sp. or Phlebotomus sp.
Geraldo Bezerra da Silva Junior, Elvino José Guardão Barros, Elizabeth De Francesco Daher   +2 more
doaj   +1 more source

ANÁLISE DOS FATORES QUE INFLUENCIAM A OCORRÊNCIA DA LEISHMANIOSE VISCERAL HUMANA

Cogitare Enfermagem, 2021
Objective: to analyze the factors that influence the occurrence of Human Visceral Leishmaniasis in the state of Paraíba, Brazil. Methods: ecological study, developed with data from 2012 to 2017, collected in a reference laboratory in the state and in the
Allan Batista Silva, Francisca Inês de Sousa Freitas, Clélia de Alencar Xavier Mota, Maria Eliane Moreira Freire, Hemílio Fernandes Campos Coêlho, Caliandra Maria Bezerra Luna Lima   +5 more
doaj   +1 more source

Perceived quality of life among Visceral Leishmaniasis and HIV coinfected migrant male-workers in Northwest Ethiopia: a qualitative study

BMC Public Health, 2017
Background There is paucity of data on quality of life as a dimension of treatment outcome among Visceral Leishmaniasis and HIV coinfected patients. This study sought to explore perceived quality of life among Visceral Leishmaniasis and HIV coinfected ...
Mekuriaw Alemayehu, Mamo Wubshet, Nebiyu Mesfin, Abebaw Gebayehu   +3 more
doaj   +1 more source

Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy

Frontiers in Immunology, 2019
Leishmaniasis is a parasitic disease of humans, highly prevalent in parts of the tropics, subtropics, and southern Europe. The disease mainly occurs in three different clinical forms namely cutaneous, mucocutaneous, and visceral leishmaniasis (VL).
A. Dayakar, S. Chandrasekaran, S. Kuchipudi, Suresh K. Kalangi   +3 more
semanticscholar   +1 more source

Presentation of AIDS with Disseminated Cutaneous and Visceral Leishmaniasis in Iran

Case Reports in Infectious Diseases, 2015
Leishmaniasis is an infectious disease in form of visceral (VL), cutaneous (CL), and mucocutaneous (MCL) leishmaniasis. Immunocompromised patients have increased risk of Leishmania infection, especially in endemic areas for visceral leishmaniasis, where
Mohammadali Davarpanah, Masumeh Rassaei, Fatemeh Sari aslani   +2 more
doaj   +1 more source

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance Safer and more effective oral drugs are urgently required to treat visceral leishmaniasis (VL), a neglected parasitic disease that kills 20,000–40,000 people each year in parts of Asia, Africa, and Latin America.
S. Wyllie, S. Brand, Michael G. Thomas, M. De Rycker, C. Chung, Imanol Peña, Ryan P. Bingham, Juan A. Bueren-Calabuig, J. Cantizani, D. Cebrián, P. Craggs, L. Ferguson, P. Goswami, J. Hobrath, Jonathan R Howe, Laura Jeacock, E. Ko, J. Korczynska, Lorna M MacLean, Sujatha Manthri, M. Martínez, Lydia Mata-Cantero, S. Moniz, Andrea Nühs, Maria Osuna-Cabello, É. Pinto, Jennifer Riley, Sharon A Robinson, P. Rowland, Frederick R. C. Simeons, Y. Shishikura, D. Spinks, L. Stojanovski, John Thomas, S. Thompson, Elisabet Viayna Gaza, Richard J. Wall, F. Zuccotto, D. Horn, M. Ferguson, A. Fairlamb, J. Fiandor, Julio Martin, David W. Gray, T. Miles, I. Gilbert, K. Read, Maria Marco, P. Wyatt   +48 more
semanticscholar   +1 more source

Treatment of visceral leishmaniasis

Journal of Global Infectious Diseases, 2010
The available treatment options for visceral leishmaniasis (VL) have problems relating to efficacy, adverse effects and cost, making treatment a complex issue. We review the evidence relating to the different methods of treatment in relation to - efficacy and toxicity of the drugs in different areas of the world; ability to monitor side effects, length
E M Moore, D N Lockwood
openaire   +4 more sources

A case of visceral leishmaniasis imported from Armenia

Детские инфекции (Москва), 2023
The relevance of the problem of visceral leishmaniasis is due to the severity of clinical manifestations, as well as the need for immediate etiotropic therapy.
A. L. Rossina, S. B. Chuelov, N. V. Kondratenko, E. V. Tselovalnikova, A. V. Tebenkov, S. V. Kolyagina, N. A. Sokolova, N. V. Nepokulchitskaya   +7 more
doaj   +1 more source

Eliminating visceral leishmaniasis in South Asia: the road ahead

British medical journal, 2019
Suman Rijal and colleagues highlight lessons from a regional collaboration to eliminate visceral leishmaniasis and identify priorities for the post-elimination ...
S. Rijal, S. Sundar, D. Mondal, P. Das, J. Alvar, M. Boelaert   +5 more
semanticscholar   +1 more source